

## Antibodies against *Candida albicans* Antigens

The diploid, unicellular yeast *Candida albicans* is an important commensal pathogen that colonizes the skin and mucosal surfaces of 30-70% of all humans (Dühring *et al.* 2015). In healthy individuals, *C. albicans* is controlled by the normal microbial flora, epithelial barriers, and the immune system. In situations when this homeostasis becomes imbalanced, e.g. burns leading to the destruction of epithelial barriers or a compromised immune system, a *C. albicans* infection, candidiasis, can develop (Gow and Hube 2012; Dühring *et al.* 2015). Superficial infections of the oral and vaginal mucosa are the most common forms of candidiasis. It is estimated that approximately 75% of all women suffer from vulvovaginal candidiasis at least once in their lifetime and up to 50% from recurrent infections. Especially in immunocompromised individuals, *C. albicans* can cause systemic infections by entering the blood stream (candidemia) and disseminating further through the body to infect virtually any organ. Mortality rates of up to 50% have been reported for these systemic infections (Sudbery 2011; Dühring *et al.* 2015).

Glucan 1,3-beta-glycosidase (Bgl2) is a cell wall localized 1,3-beta-glycosyltransferase, whose deletion negatively affects *C. albicans* virulence (Hartland *et al.* 1991; Sarthy *et al.* 1997). In 2006, Pitarch *et al.* analyzed sera from patients diagnosed with systemic candidiasis and found all to be positive for anti-Bgl2 antibodies.

*C. albicans* enolase is a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate and is localized in both the cytoplasm and the cell wall (Angiolella *et al.* 1996). Depending on the study, antibodies against this protein have been reported in approximately 50-90% of patients (Mitsutake *et al.* 1994; van Deventer *et al.* 1994; Lain *et al.* 2007).

The heat shock protein 70 (Hsp70) family comprises molecular chaperones involved in the synthesis and transport of proteins. In *C. albicans*, the cytoplasmic Hsp70

### Ordering Information

44800	<i>Candida albicans</i> Bgl2	0.1 mg
44801		1.0 mg
45300	<i>Candida albicans</i> Enolase	0.1 mg
45301		1.0 mg
45400	<i>Candida albicans</i> Hsp70	0.1 mg
45401		1.0 mg
44900	<i>Candida albicans</i> Met6	0.1 mg
44901		1.0 mg




Figure: Immunodot analyses of sera from a blood donor (BD) and of patients infected with *Candida albicans* (PS 1-4) for the presence of antibodies against recombinant *C. albicans* Bgl2, Enolase, Hsp70, and Met6. The proteins were printed on nitrocellulose membranes as indicated.

or SSA1 also localizes to the cell wall and functions in the adhesion to host cells. Further, it reacts with patient sera in immunoassays (La Valle *et al.* 1995; López-Ribot *et al.* 1996; Bromuro *et al.* 1998; Chaffin *et al.* 1998).

*C. albicans* methionine synthase (Met6) is an essential, cobalamin-independent enzyme involved in the synthesis of methionine (Jones *et al.* 2004; Suliman *et al.* 2007) and has been reported as a major antigen in patients suffering from systemic candidiasis (Pardo *et al.* 2000; Pitarch *et al.* 2006).

DIARECT's *Candida albicans* Bgl2, Enolase, Hsp70, and Met6 are produced in the baculovirus/insect cell expression system.

### References:

- Angiolella *et al.* (1996) *J Infect Dis.* 173:684-690  
 Bromuro *et al.* (1998) *Infect Immun.* 66:2154-2162  
 Chaffin *et al.* (1998) *Microbiol Mol Biol Rev.* 62:130-180  
 Dühring *et al.* (2015) *Front Microbiol.* 6:625  
 Gow and Hube (2012) *Curr Opin Microbiol.* 15:406-412  
 Hartland *et al.* (1991) *Proc Biol Sci.* 246: 155-160  
 Jones *et al.* (2004) *Proc Natl Acad Sci USA.* 101:7329-7334  
 La Valle *et al.* (1995) *Infect immun.* 63:4039-4045  
 Lain *et al.* (2007) *Clin Vaccine immunol.* 14:318-319  
 López-Ribot *et al.* (1996) *Infect Immun.* 64:3333-3340  
 Mitsutake *et al.* (1994). *J Clin Lab Anal.* 8:207-210  
 Pardo *et al.* (2000) *Electrophoresis.* 21:2651-2659  
 Pitarch *et al.* (2006) *Mol Cell Proteomics.* 5:79-96  
 Sarthy *et al.* (1997) *Microbiology.* 143:367-376  
 Sudbery (2011) *Nat Rev Microbiol.* 9:737-748  
 Suliman *et al.* (2007) *Arch Biochem Biophys* 467:218-226  
 van Deventer *et al.* (1994) *J Clin Microbiol.* 32:17-23

In some countries the use of certain antigens in diagnostic tests may be protected by patents. DIARECT is not responsible for the determination of these issues and suggests clarification prior to use.

151027\_Rev01

